好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Risk factors for readmission in a nationally representative sample of children with epilepsy
Epilepsy/Clinical Neurophysiology (EEG)
P3 - Poster Session 3 (5:30 PM-6:30 PM)
6-025

To evaluate risk factors for 30-day unplanned readmission in children with epilepsy.

Epilepsy is a common but complex disorder in children, whose costs are driven in part by inpatient hospitalization for seizures. Reduction in readmission rates has been a focus of hospital quality-improvement efforts, but rates and risk factors for epilepsy readmissions are unclear.

 

 

We used the Nationwide Readmissions Database years 2013-2014 to conduct a retrospective cohort study of children 1-17 years-old who had the admitting diagnosis epilepsy (ICD9 345.x). The NRD is the only nationally representative data source on hospitalizations/readmissions for all ages and payers, including uninsured patients. The NRD contains data from 22 states, including 51.2% of the U.S. population and 49.3 percent of all U.S hospitalizations. The primary outcome measure was percent readmitted within 30 days. We examined socio-demographic, clinical, and hospital characteristics as predictors of readmission, and report adjusted odds ratios.

We identified 42,873 index admissions chiefly in large(70.3%), metropolitan teaching hospitals (91%). Patients were more often male (54.6%), 4-12 years old (50.8%), and Medicaid participants (61.5%). Status epilepticus occurred in 24.6%, and 20.6% underwent continuous EEG monitoring. The 30-day readmission rate was 10%. Readmission was more likely in children aged 1-3 years than in children aged 4-12 years (AOR 0.84, 95%CI 0.72-0.97) or 13-17 years (AOR 0.75, 95%CI 0.63-0.88). Status epilepticus during index admission was not a risk factor for readmission (AOR 0.9 (0.77-1.06), but comorbid intellectual disability, developmental delay, cerebral palsy, tracheostomy, and gastrostomy each increased the risk of readmission (AOR ranged from 1.17 to 2.04). A diagnosis of intractable epilepsy was also associated with higher readmission rates (AOR 1.53, 95%CI 1.28-1.82).

The burden of unplanned readmissions in pediatric epilepsy may fall on younger children with complex comorbidities. Focusing on this population may improve the effectiveness of future interventions to reduce readmissions.

Authors/Disclosures
Sudha Kessler, MD (Children's Hospital of Philadelphia)
PRESENTER
Dr. Kessler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Efficient CME. Dr. Kessler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda Pharmaceuticals. The institution of Dr. Kessler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for The Epilepsy Study Consortium. Dr. Kessler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Kessler has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Wilson, Elser. The institution of Dr. Kessler has received research support from FDA, Commonwealth of Pennsylvania, Epilepsy Study Consortium, UCB Pharma, Greenwich Biosciences, Eisai Co. Ltd.. PCORI/AHRQ, SK Life. Dr. Kessler has a non-compensated relationship as a volunteer committee member with American Epilepsy Society that is relevant to AAN interests or activities. Dr. Kessler has a non-compensated relationship as a committee member with American Board of Psychiatry and Neurology that is relevant to AAN interests or activities.
Shavonne Massey, MD (Children'S Hospital of Philadelphia) Dr. Massey has a non-compensated relationship as a consultant with Sun Pharmaceutical Ltd that is relevant to AAN interests or activities.
Nicholas S. Abend, MD, FAAN (Children's Hospital of Philadelphia) Dr. Abend has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Epilepsy Foundation. The institution of Dr. Abend has received research support from NIH. The institution of Dr. Abend has received research support from PCORI. Dr. Abend has received publishing royalties from a publication relating to health care.
Allison Wright Willis, MD (University of Pennsylvania) Dr. Wright Willis has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pharmacoepidemiology and Drug Safety. Dr. Wright Willis has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. The institution of Dr. Wright Willis has received research support from NIH. The institution of Dr. Wright Willis has received research support from NIA. The institution of Dr. Wright Willis has received research support from Biogen. The institution of Dr. Wright Willis has received research support from Parkinson Foundation. The institution of Dr. Wright Willis has received research support from Arcadia.